MAXON™ and MAXON™ CV synthetic absorbable sutures are prepared from polyglyconate, a copolymer of glycolic acid and trimethylene carbonate
MAXON™ and MAXON™ CV synthetic absorbable sutures are indicated for use in general soft tissue approximation and/or ligation, including use in pediatric cardiovascular tissue, where growth is expected to occur, and in peripheral vascular surgery
MAXON™ and MAXON™ CV synthetic absorbable sutures are not indicated for use in adult cardiovascular tissue, ophthalmic surgery, microsurgery and neural tissues
MAXON™ sutures retain approximately 75% of initial tensile strength at two weeks, 65% of at three weeks and 50% at four weeks post-implant
Absorption of MAXON™ sutures is minimal until about 60 days after implant and is essentially complete within six months
This product is required to be reported under California Proposition 65
